AnaptysBio (ANAB) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AnaptysBio (ANAB) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 117.8% versus a loss of 50.5%. Over five years, ANAB leads with a +141.8% price change compared with -80.9% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.52 billion vs $1.38 billion), about 1.1 times the size.
On valuation, AnaptysBio trades at a lower forward P/E (9.1x vs 22.8x for Ultragenyx Pharmaceutical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | RARE |
|---|---|---|
| Share price | $46.15 | $15.45 |
| Market cap | $1.38B | $1.52B |
| 1-day change | -0.13% | +1.05% |
| YTD return | +42.98% | -33.52% |
| 1-year return | +117.77% | -50.45% |
| 5-year return | +141.77% | -80.89% |
| Forward P/E | 9.11 | 22.83 |
| EPS (TTM) | $-0.96 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | — | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $72.36 | $39.89 |
| 52-week low | $20.18 | $12.73 |
| Distance from 52-week high | -36.22% | -61.27% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +89.06% | +81.55% |
| Average volume | 565.82K | 3.87M |
| Shares outstanding | 29.90M | 98.59M |
| Employees | — | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed RARE by 168.2 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
ANAB vs RARE FAQ
Which is bigger, AnaptysBio or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.52B compared with $1.38B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or RARE?
ANAB returned +117.77% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.